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Background: Altered plasma concentrations of vitamin D and mannose binding lectin (MBL), components of innate
immunity, have been shown to be associated with the pathogenesis of viral infections. The objective of the present
study was to find out whether plasma concentrations of MBL and vitamin D are different in patients with dengue
fever (DF) and dengue hemorrhagic fever (DHF).
The results: The plasma concentrations of vitamin D and MBL were assessed in 48 DF cases, 45 DHF cases and 20
apparently healthy controls using ELISA based methods. Vitamin D concentrations were found to be higher among
both DF and DHF cases as compared to healthy controls (P< 0.005 and P< 0.001). Vitamin D concentrations were
not different between DF and DHF cases. When the dengue cases were classified into primary and secondary
infections, secondary DHF cases had significantly higher concentrations of vitamin D as compared to secondary DF
cases (P< 0.050). MBL concentrations were not significantly different between healthy controls and dengue cases.
MBL concentrations were observed to be lower in DHF cases as compared to DF cases (P< 0.050). Although MBL
levels were not different DF and DHF cases based on immune status, the percentage of primary DHF cases (50%)
having MBL levels lower than 500 ng/ml were less compared to primary DF cases (P= 0.038).
Conclusions: The present study suggests that higher concentrations of vitamin D might be associated with
secondary DHF while deficiency of MBL may be associated with primary DHF.
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Dengue, caused by dengue virus (DENV), constitutes a
public health emergency of international concern. DENV
infection in humans results in a spectrum of outcomes
ranging from asymptomatic to undifferentiated fever,
mild form of the disease namely dengue fever (DF) to se-
vere forms including dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) that may be fatal [1].
The outcome of DENV infection is determined by mul-
tiple factors including viral virulence, host genetics and
host immune responses [2].* Correspondence: cecilia.dayaraj@gmail.com
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responses, T cells, antibodies, cytokine storm and
complement factors contribute to the pathogenesis of den-
gue [2]. Epidemiological studies have shown an association
between DHF/DSS and secondary DENV infection. Preex-
isting antibodies and cross reactive T cell responses induced
by the primary infection is believed to exacerbate the
disease during secondary infection [3,4]. Proinflammatory
cytokines namely interleukin-8 (IL-8), tumor necrosis
factor-α and interferon-γ and anti inflammatory
cytokine IL-10 also contribute to dengue disease pathogen-
esis [5-11]. Activation of T cells, antibodies and cytokines
are influenced by various immunomodulators. Increase or
decrease in the levels of these immunomodulators
influences the outcome of viral infections [12].
Vitamin D is a potent immunomodulator affecting
both innate and adaptive immune responses. Vitamin D
binds to Vitamin D receptor (VDR), translocates to theral Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.










Age* 29.5 (11–65) 23.0 (4–58) 0.026
Immune status** 20 Primary (42.5) &
27 secondary (57.4.)
8 primary (18.6) &
35 secondary (81.3)
0.040
Fever 48 (100.0) 45 (100.0) 1.000
Headache 24 (50.0) 23 (51.1) 0.920
Myalgia 28 (58.3) 22 (48.9) 0.480
Arthralgia 7 (14.6) 9 (20.0) 0.670
Nausea/Vomitting 0 12 (26.7) <0.001
Abdominal pain 0 5 (11.1) 0.023
Retro orbital pain 1 (2.1) 4 (8.9) 0.190
Rash 9 (18.8) 9 (20.0) 0.950
Thrombocytopenia 28 (58.3) 41 (91.1) <0.001
Platelet count* 67000 (13000–330000) 38500 (5000–150000) 0.002
*Age and platelet counts are represented in the form of median values with
ranges in the parenthesis and compared between DF and DHF cases using
Mann–Whitney U test.
**For determining immune status, only 47 DF and 43 DHF samples were
available.
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enhances the phagocytic capacity of macrophages and
induces antimicrobial peptide gene expression contribut-
ing to innate immune responses [13]. Vitamin D inhibits
T-helper 1 (Th1) cell and cytotoxic T cell responses. It
decreases B-cell proliferation, plasma-cell differentiation
and IgG secretion [14]. Vitamin D also enhances Th2
cytokine and IL-10 responses [15,16]. Vitamin D
deficiency increases the risk of cancer, tuberculosis, as
well as influenza and human immunodeficiency virus
infection [12,17,18]. Vitamin D has been reported to
influence the expression of DENV receptors in immune
cells [19-21]. A study from Vietnam has shown the asso-
ciation of vitamin D receptor gene polymorphisms with
susceptibility to DHF [22].
One of the major pathways of complement activation
is initiated by binding of the virus to mannose binding
lectin (MBL). MBL is a pattern recognition molecule that
recognizes specific sugar molecules present on the
surface of microorganisms including DENV [23,24].
Point mutations in the MBL2 gene lead to reduced
concentrations of functional oligomers. Genetically
determined variation in serum concentrations of MBL
has been shown to influence the susceptibility to
infectious, autoimmune and cardiovascular diseases [23].
Alleles of MBL2 gene that are associated with higher
concentrations of functional MBL, have been shown to
be associated with thrombocytopenia in dengue infected
patients [25]. MBL concentrations were also found to be
increased in acute samples of DHF cases as compared to
DF cases [26].
Since MBL and Vitamin D are known to influence
innate and adaptive immune responses and DENV
pathogenesis is immune mediated, we hypothesized that
altered levels of plasma vitamin D and MBL might be
associated with dengue disease severity. Therefore, we
investigated the levels of plasma vitamin D and MBL in
dengue infected patients in the context of disease
severity and immune status.
Results
Demographic and clinical characteristics of patients
Among the 93 patients included in the study, based on the
DF/DHF defining criteria of the World Health
Organization (WHO) [27], 48 had DF and 45 had DHF.
Males were over represented in both DF and DHF
patients. The male to female ratio in DF was 2:0.76 and in
DHF, it was 2:1. Demographic and clinical characteristics
of patients were given in Table 1. The median age of DHF
cases (23.0 years) was significantly lower than that of DF
cases (29.5 years) (P=0.034). The number of primary cases
with DF (42.5%) was higher than the number of primary
cases with DHF (18.6%) (P=0.026). When the presence of
clinical symptoms was compared between DF and DHFcases, the presence of fever with chills, headache, myalgia,
arthralgia, retro orbital pain and rash were reported equally
in DF and DHF cases. Presence of nausea/vomiting and ab-
dominal pain was represented by the DHF cases.
Thrombocytopenia was significantly over represented in
DHF cases as compared to DF cases (P< 0.001). The me-
dian count of platelets was significantly lower in DHF cases
(P=0.020) (Table 1).
Among the 45 DHF cases, gastrointestinal bleeding,
manifested by melena or hematemesis was reported in
21 (46.7%) cases, hematuria was observed in six (13.3%),
gum bleeding in seven (15.6%), conjunctival hemorrhage
in one (2.2%) and epistaxis in one (2.2%). Plasma leakage
was observed in 9 (20%) patients either as ascites (n = 5)
and/or as pleural effusion (n = 4). Shock/hypotension was
observed in five patients (11.1%). No fatality was
observed in the cases included in the study.Plasma concentrations of vitamin D in dengue patients
Plasma 25-hydroxy vitamin D3 (vitamin D) concentrations
were investigated in 45 DF cases, 38 DHF cases and 20
healthy controls. Vitamin D concentrations were found to
be significantly higher in DF and DHF cases as compared
to healthy controls (healthy controls vs. DF cases P< 0.005;
healthy controls vs. DHF cases P< 0.001). Among DF and
DHF cases, the vitamin D concentrations were found to be
higher in DHF cases, though, the difference was not statis-
tically significant (P> 0.050) (Figure 1). The sample size
has a power of 0.94 and 0.80 to detect the differences
Figure 1 25-hydroxy vitamin D concentrations in DF cases, DHF
cases and healthy controls. 25-hydroxy vitamin D concentrations
were expressed in ng/ml and plotted in form of a scatter plot. The
lines represent median value with interquartile ranges. The number
of samples for DF is 45, 38 for DHF and 20 for healthy controls. Figure 2 25-hydroxy vitamin D concentrations in DF cases and
DHF cases based on the host immune status. 25-hydroxy vitamin
D concentrations were expressed in ng/ml and plotted in form of a
scatter plot. The lines represent median value with interquartile
ranges. The number of samples for primary DF is 19, 7 for primary
DHF, 25 for secondary DF and 31 for secondary DHF.
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DF and healthy controls respectively.Vitamin D levels in the context of immune status and
disease severity
When the patients were grouped based on immune
status and disease severity, secondary DHF cases had
significantly higher concentrations of vitamin D as
compared to secondary DF cases (P< 0.050). The sample
size has a power of 0.79 to detect the differences
observed between secondary DF and secondary DHF
cases. Vitamin D concentrations were not significantly
different between primary DF and primary DHF cases
(P> 0.050). When comparisons were made between
primary DF and Secondary DF or primary DHF and
secondary DHF, vitamin D levels were not different
(P> 0.050) (Figure 2).Figure 3 Mannose binding lectin levels in DF cases, DHF cases
and healthy controls. Mannose binding lectin levels were
expressed in ng/ml and plotted in form of a scatter plot. The lines
represent median value with interquartile ranges. The number of
samples for DF is 48, 45 for DHF and 20 for healthy controls.Plasma MBL concentrations in dengue patients
Plasma MBL concentrations were assessed in 48 DF
cases, 45 DHF cases and 20 healthy controls. MBL con-
centrations were not significantly different between
healthy controls and DF or DHF cases (P> 0.050). When
DF and DHF cases were compared, significantly lower
concentrations of MBL were observed in DHF cases
(P< 0.050) (Figure 3). The sample size has a power of
0.52 to detect the observed differences between DHF
and DF cases. The sample size is underpowered to detect
the differences (effect size of less than 0.5) observed
between DF and healthy controls or DHF and healthy
controls. However, the sample size has a power of above
0.80 to detect an effect size of 0.8 and above.Plasma MBL concentrations in the context of immune
status and disease severity
When the patients were classified into primary and
secondary cases and compared, irrespective of DF or
DHF, MBL concentrations were not different (P> 0.050).
MBL concentrations were lower in primary DHF cases as
compared to primary DF cases though not statistically
significant. MBL levels were not different between
secondary DF and secondary DHF (Figure 4).
Figure 4 Mannose binding lectin levels in DF and DHF cases
based on the host immune status. Mannose binding lectin levels
were expressed in ng/ml and plotted in form of a scatter plot. The
lines represent median value with interquartile ranges. The number
of samples for primary DF is 20, 8 for primary DHF, 27 for secondary
DF and 35 for secondary DHF.
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deficiency
Since MBL level varies as a function of multiple
polymorphisms of MBL2 gene, a cutoff value of 500 ng/ml
was used to define subjects with or without MBL
deficiency. Based on the cutoff value, 40% of DHF cases,
25% of DF cases and 35% of the healthy controls had
deficiency of MBL. When the patients were grouped based
on disease severity and immune status, 50% of primary
DHF cases had MBL deficiency as compared to 10% of
primary DF cases (p=0.038, Odds ratio (OR) 9, 95% confi-
dence limits 0.84–120). This difference was not observed in
secondary infections with 37% of secondary DF and 40% of
secondary DHF patients having low level of MBL. Analysis
with a cutoff value indicating almost complete deficiency of
MBL (<100 ng/ml) was also performed. Results revealed
that 37.5% of primary DHF cases had an almost complete
deficiency of MBL as compared to 5% of primary DF cases
(p=0.058, OR 11.40 95% CI 0.66–628). 14.8% of secondary
DF and 14.2% of secondary DHF patients had an almost
complete deficiency of MBL.Discussion
In the present study, plasma concentrations of vitamin D
and MBL were investigated in dengue patients from
Pune, Maharashtra, western India. Pune is endemic to
dengue with 600–800 cases occurring annually. All four
serotypes have been reported to be circulating in Pune
[28]. The demographic and clinical characteristics
reported in the present study were similar to that
reported in our earlier study [5].Investigation of vitamin D concentrations revealed
significantly higher concentrations of vitamin D in
dengue patients (both DF and DHF) as compared to
apparently healthy controls suggesting that higher con-
centrations of vitamin D might be associated with symp-
tomatic disease. Further analysis revealed that the
association was more evident in secondary DHF. It has
been shown that vitamin D induces expression of
dendritic cell specific intercellular adhesion molecule 3
grabbing non integrin (DC-SIGN), the primary receptor
for DENV entry into immature dendritic cells [19]. It has
also been shown that calcitriol (active form of vitamin
D) increases the expression of Fcγ receptors on human
monocytic cell lines and monocyte derived dendritic cells
[20,21]. The increased concentrations of vitamin D, in
DENV infected cases with secondary infection, might
enhance viral entry through increased expression of Fcγ
receptors leading to higher viral load, uncontrolled
inflammatory responses and subsequent development of
DHF. Vitamin D is also known to suppress Th1
cytokines and enhance IL-10 production by peripheral
blood mononuclear cells in response to microbial
antigens [14-16]. Since IL-10 is known to play a role in
dengue disease pathogenesis [11], it is possible that
vitamin D could also contribute to disease pathogenesis
through altered IL-10 response. Since the effect of
vitamin D is also dependent on single nucleotide
polymorphisms in the VDR gene [29], the influence of
vitamin D on dengue in the context of host genetics
needs to be investigated.
Analysis of circulating concentrations of MBL in
dengue cases and healthy controls revealed no significant
difference between the two groups suggesting that the
MBL mediated pathway of complement activation might
be inhibited or may not be induced during DENV infec-
tion. Deficiency of MBL has been reported in patients
infected with other RNA viruses such as Crimean-Congo
hemorrhagic fever virus, respiratory syncytial virus and
severe acute respiratory syndrome (SARS) corona virus
[30-32]. Interaction between complement components
and non structural protein 1 (NS1) of flaviviruses has
been reported to inhibit classical and lectin pathways of
complement activation [33]. The present study revealed
significantly lower levels of MBL in DHF cases suggest-
ing that reduced activation of MBL mediated comple-
ment pathway might be associated with DHF. MBL is
known to interact with N- linked glycans of structural
proteins of DENV and neutralize the virus by blocking
viral fusion. In experimentally infected mice, MBL
dependent intravascular clearance of DENV has also
been reported [24]. Therefore, it is possible that MBL
deficiency might have led to decreased activation of
MBL mediated pathway of complement and reduced
intravascular clearance of DENV leading to higher viral
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with DHF in several studies [34,35].
In the present study, deficiency of MBL was more
evident in cases with primary DHF. The association of
MBL deficiency with DHF in primary infection also sug-
gests that the protective effects of MBL and the innate
immune responses are more important during primary in-
fection which could be overshadowed by presence of cross
reactive complement fixing antibodies during secondary
infection [36]. In contrast to the present study, a study
from Brazil has reported higher concentrations of MBL
among DHF cases [7]. A higher MBL concentration might
also lead to increased inflammation through enhancement
of the production of pro-inflammatory cytokines. Increased
concentration of factor D and decreased concentration of
factor H have been reported in DHF cases suggesting that
imbalance in the regulation of factors H and D of the alter-
native pathway of complement activation is associated with
DHF [26]. Since MBL concentrations are dependent on the
presence of mutations in the structural and promoter
regions of MBL2 gene, it is possible that variant alleles
of MBL2 gene polymorphisms might be associated with
DHF. A case control study from Brazil has shown the asso-
ciation of wild type alleles of the MBL2 gene with
thrombocytopenia in dengue patients [25]. Further case
control studies are needed to confirm the phenotypic
effects of MBL2 gene polymorphisms in dengue patients
with primary infection from India. Although, the present
study is sufficiently powered to detect intermediate to large
effect size, with regard to MBL, the study is underpowered
and further studies with larger sample size are needed to
confirm the preliminary associations.
Conclusions
The present study suggests that higher concentrations of
vitamin D are associated with secondary DHF. This asso-
ciation may be related to the inducing effect of vitamin
D on Fcγ receptor expression which might subsequently
lead to higher viral load in dengue cases with secondary
infection and hence development of DHF. The study also
suggests that MBL deficiency is associated with primary
DHF. This association might be related to the reduced
activation of the MBL pathway of complement leading to
higher viral load in dengue cases with primary infection.
This is the first study that correlates the concentrations




Blood samples from patients with dengue like illness
were referred to the National Institute of Virology for
diagnosis. Samples were transported on ice and plasma
was separated and aliquoted. One aliquot was used fordengue specific IgM ELISA and leftover aliquots were
stored in -80°C. A total number of 93 samples, which
were positive for dengue specific IgM ELISA, were
included in the study. All the samples were collected
during the seasonal outbreak in Pune in 2009. Clinical
presentations of the patients recorded by the clinicians
were used to classify the patients. The patients were clas-
sified into those with DF and those with DHF. Patients
with fever, headache, myalgia, retro-orbital pain, and rash
were defined as DF. DHF patients were categorized by
the presence of at least two of the DHF defining criteria
of the WHO [27]: hemorrhagic tendencies/manifesta-
tions, thrombocytopenia, and evidence of plasma
leakage. Samples from 20 apparently healthy blood
donors were also used in the study. This study was
approved by the National Institute of Virology Human
Ethics Committee. Waiver of the informed consent was
granted by the committee on the basis of “Use of leftover
specimens after clinical investigation” under the Indian
Council of Medical Research Guidelines 2006.
Laboratory diagnosis
The in-house National Institute of Virology (NIV) IgM
capture ELISA kit was used to detect DENV-specific
IgM. A known positive (P) and a known negative (N)
serum control were used in every test. A sample showing
P/N ratio >2.1 times the optical density was considered
positive. The IgG capture ELISA (E-DEN02G, Panbio,
Windsor, Australia) was used to classify the cases into
primary or secondary DENV infection. IgG levels of >22
units (defined by the manufacturers) indicated secondary
infection.
Estimation of Vitamin D and MBL concentrations
25-hydroxyvitamin D3 (vitamin D) was quantitated in the
plasma samples using an enzyme immunoassay kit (IDS
Ltd, UK) according to the manufacturer’s protocol. Calibra-
tors and controls were used in each assay. The percent
binding (B/B%) of each calibrator, control and unknown
samples were calculated by the following formula: B/B
%=mean absorbance/mean absorbance for ‘0’ calibrator
x100. A calibration curve with B/B% and vitamin D concen-
trations were used to find out the concentrations of vitamin
D in unknown samples in nm/L. The detection limit of the
kit is 5 nm/L.
Estimation of plasma MBL concentrations was done
using the MBL oligomer ELISA kit (BioPorto Diagnos-
tics, Denmark) according to the manufacturer’s instruc-
tions. Calibrators were used in each assay and a
calibration curve was constructed by plotting the mean
absorbance values for each calibrator on the y-axis
against the corresponding MBL concentrations in ng/ml
on the x-axis. The MBL concentration of each diluted
plasma sample was then found by locating the point on
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diluted plasma sample and reading its corresponding
concentration in ng/ml from the x-axis. The concentra-
tion of MBL in the undiluted plasma sample is calculated
by multiplying this result by the sample dilution factor.
The detection limit of the kit is 2 ng/ml.
Statistical analysis
Using the Statcalc program (Epi info version 6.0.4, CDC,
Atlanta, GA, July 1996), the chi-square test with Yates
correction or Fisher exact test (when any cell value was
less than 5) was performed to examine differences in
demographic and clinical characteristics of the dengue
patients. Age and platelet counts were compared using
Mann–Whitney U test. Concentrations of MBL and 25
[OH]D in plasma samples were compared between study
groups using Kruskal-Wallis test with Dunn’s multiple
comparison for selected groups. The P values from
Dunn’s multiple comparison for selected groups were
provided.
Since MBL levels varies depending on the presence of
polymorphisms in the MBL2 gene, categorization of
study subjects based on MBL deficiency (defined by a
cutoff value of <500 ng/ml) was done and compared be-
tween study groups using the chi-square test with Yates
correction or Fisher exact test. This cutoff value
(<500 ng/ml) has been earlier shown to be a reliable
predictor of low producing MBL2 genotypes using re-
ceiver operating characteristic analysis with individual
data from 1642 healthy subjects from 4 studies [37].
All statistical analysis was performed using Graphpad
prism (version 4). A Two tailed P value less than 0.05
was considered significant. Power calculations were per-
formed using the software G*Power version 3.1.3. The
achieved power for significant results were calculated using
the Wilcoxon-Mann–Whitney test (two groups) option
available in ‘t’ test family of the software. The sample size,
level of significance and effect size were provided as input.
For calculating the effect size, the software uses mean
values with standard deviation of the two groups [38].
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